A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus

The current unprecedented outbreak of Ebola virus (EBOV) disease in West Africa has demonstrated the urgent need for a vaccine. Here, we describe the evaluation of an EBOV vaccine candidate based on Kunjin replicon virus-like particles (KUN VLPs) encoding EBOV glycoprotein with a D637L mutation (GP/D637L) in nonhu-man primates. Four African green monkeys (Cercopithecus aethiops) were injected subcutaneously with a dose of 109 KUN VLPs per animal twice with an interval of 4 weeks, and animals were challenged 3 weeks later in-tramuscularly with 600 plaque-forming units of Zaire EBOV. Three animals were completely protected against EBOV challenge, while one vaccinated animal and the control animal died from infection. We suggest that KUN VLPs encoding GP/D637L represent a viable EBOV vaccine candidate. Keywords. Ebola virus; Kunjin replicon; vaccine; nonhuman primates. Ebola virus (EBOV) is responsible for a severe form of viral hemorrhagic fever in humans, with case-fatality rates of up to 90%. Outbreaks of Ebola disease were first documented in 1976 in the African countries Zaire (now Democratic Republic of the Congo) and Sudan [1]. Since then, a number of outbreaks hav